|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chan S, Friedrichs K, Noel D, Pintér T,
Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E,
et al; 303 Study Group. Prospective randomized trial of docetaxel
versus doxorubicin in patients with metastatic breast cancer. J
Clin Oncol. 17:2341–2354. 1999.PubMed/NCBI
|
|
3
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R; Gynecologic Oncology Group. Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paik S, Kim C and Wolmark N: HER2 status
and benefit from adjuvant trastuzumab in breast cancer. N Engl J
Med. 358:1409–1411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aydiner A and Tas F: Meta-analysis of
trials comparing anastrozole and tamoxifen for adjuvant treatment
of postmenopausal women with early breast cancer. Trials. 9:472008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pecorelli S, Favalli G, Gadducci A,
Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O
and Conte P; After 6 Italian Cooperative Group. Phase III trial of
observation versus six courses of paclitaxel in patients with
advanced epithelial ovarian cancer in complete response after six
courses of paclitaxel/platinum-based chemotherapy: Final results of
the After-6 protocol 1. J Clin Oncol. 27:4642–4648. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L, Conejo-Garcia JR, Katsaros D,
Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H,
Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med.
348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Curiel TJ, Coukos G, Zou L, Alvarez X,
Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L,
Burow M, et al: Specific recruitment of regulatory T cells in
ovarian carcinoma fosters immune privilege and predicts reduced
survival. Nat Med. 10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast
cancer. J Clin Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Napoletano C, Bellati F, Landi R, Pauselli
S, Marchetti C, Visconti V, Sale P, Liberati M, Rughetti A, Frati
L, et al: Ovarian cancer cytoreduction induces changes in T cell
population subsets reducing immunosuppression. J Cell Mol Med.
14:2748–2759. 2010. View Article : Google Scholar
|
|
11
|
Bellati F, Napoletano C, Ruscito I,
Visconti V, Antonilli M, Gasparri ML, Zizzari IG, Rahimi H, Palaia
I, Rughetti A, et al: Past, present and future strategies of
immunotherapy in gynecological malignancies. Curr Mol Med.
13:648–669. 2013. View Article : Google Scholar
|
|
12
|
Hueman MT, Stojadinovic A, Storrer CE,
Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S and Peoples GE:
Analysis of naïve and memory CD4 and CD8 T cell populations in
breast cancer patients receiving a HER2/neu peptide (E75) and
GM-CSF vaccine. Cancer Immunol Immunother. 56:135–146. 2007.
View Article : Google Scholar
|
|
13
|
Tsuruma T, Iwayama Y, Ohmura T,
Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe
T, Toyota N, et al: Clinical and immunological evaluation of
anti-apoptosis protein, survivin-derived peptide vaccine in phase I
clinical study for patients with advanced or recurrent breast
cancer. J Transl Med. 6:242008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuan J, Gallardo HF, Rasalan T,
Ranganathan R, Wang J, Zhang Y, Panageas K, Stan R, Young JW,
Houghton AN, et al: In vitro expansion of Ag-specific T cells by
HLA-A*0201-transfected K562 cells for immune monitoring.
Cytotherapy. 8:498–508. 2006. View Article : Google Scholar
|
|
15
|
Horstmann E, McCabe MS, Grochow L,
Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ and Grady
C: Risks and benefits of phase 1 oncology trials, 1991 through
2002. N Engl J Med. 352:895–904. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kantoff PW, Higano CS, Shore ND, Berger
ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims
RB, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy
for castration-resistant prostate cancer. N Engl J Med.
363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thayer AM: Improving peptides. Chem Eng
News. 89:13–20. 2011.
|
|
18
|
Borghouts C, Kunz C and Groner B: Current
strategies for the development of peptide-based anti-cancer
therapeutics. J Pept Sci. 11:713–726. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao GF and Jakobsen BK: Molecular
interactions of coreceptor CD8 and MHC class I: The molecular basis
for functional co-ordination with the T-cell receptor. Immunol
Today. 21:630–636. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cho HI and Celis E: Optimized peptide
vaccines eliciting extensive CD8 T-cell responses with therapeutic
antitumor effects. Cancer Res. 69:9012–9019. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Napoletano C, Rughetti A, Landi R, Pinto
D, Bellati F, Rahimi H, Spinelli GP, Pauselli S, Sale P, Dolo V, et
al: Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for
dendritic cell-based anti-tumor immunotherapy. Int J Immunopathol
Pharmacol. 22:647–658. 2009.PubMed/NCBI
|
|
22
|
Disis ML, Gooley TA, Rinn K, Davis D,
Piepkorn M, Cheever MA, Knutson KL and Schiffman K: Generation of
T-cell immunity to the HER-2/neu protein after active immunization
with HER-2/neu peptide-based vaccines. J Clin Oncol. 20:2624–2632.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Musselli C, Ragupathi G, Gilewski T,
Panageas KS, Spinat Y and Livingston PO: Reevaluation of the
cellular immune response in breast cancer patients vaccinated with
MUC1. Int J Cancer. 97:660–667. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gilewski T, Adluri S, Ragupathi G, Zhang
S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L and
Livingston PO: Vaccination of high-risk breast cancer patients with
mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin
Cancer Res. 6:1693–1701. 2000.PubMed/NCBI
|
|
25
|
Knutson KL, Schiffman K, Cheever MA and
Disis ML: Immunization of cancer patients with a HER-2/neu, HLA-A2
peptide, 369–377 results in short-lived peptide-specific immunity.
Clin Cancer Res. 8:1014–1018. 2002.PubMed/NCBI
|
|
26
|
Salazar LG, Fikes J, Southwood S, Ishioka
G, Knutson KL, Gooley TA, Schiffman K and Disis ML: Immunization of
cancer patients with HER-2/neu-derived peptides demonstrating
highaffinity binding to multiple class II alleles. Clin Cancer Res.
9:5559–5565. 2003.PubMed/NCBI
|
|
27
|
Peoples GE, Gurney JM, Hueman MT, Woll MM,
Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG and Ponniah
S: Clinical trial results of a HER2/neu (E75) vaccine to prevent
recurrence in high-risk breast cancer patients. J Clin Oncol.
23:7536–7545. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Odunsi K, Qian F, Matsuzaki J,
Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G,
Villella J, Thomas B, et al: Vaccination with an NY-ESO-1 peptide
of HLA class I/II specificities induces integrated humoral and T
cell responses in ovarian cancer. Proc Natl Acad Sci USA.
104:12837–12842. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sabbatini P, Tsuji T, Ferran L, Ritter E,
Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C,
Bell-McGuinn K, et al: Phase I trial of overlapping long peptides
from a tumor self-antigen and poly-ICLC shows rapid induction of
integrated immune response in ovarian cancer patients. Clin Cancer
Res. 18:6497–6508. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hato SV, Khong A, de Vries IJ and
Lesterhuis WJ: Molecular pathways: The immunogenic effects of
platinum-based chemotherapeutics. Clin Cancer Res. 20:2831–2837.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hato SV, de Vries IJ and Lesterhuis WJ:
STATing the importance of immune modulation by platinum
chemotherapeutics. OncoImmunology. 1:234–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Diaz Y, Tundidor Y, Lopez A and Leon K:
Concomitant combination of active immunotherapy and carboplatin- or
paclitaxel-based chemotherapy improves anti-tumor response. Cancer
Immunol Immunother. 62:455–469. 2013. View Article : Google Scholar
|
